Publikationen, an denen er mitarbeitet Cristina Alenda González (20)

2020

  1. Clinical and Pathological Characterization of Lynch-Like Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 368-374.e1

  2. Risk of cancer in family members of patients with lynch-like syndrome

    Cancers, Vol. 12, Núm. 8, pp. 1-12

2018

  1. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy

    PLoS ONE, Vol. 13, Núm. 9

2017

  1. Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives

    Gastroenterology, Vol. 153, Núm. 1, pp. 106-112.e2

2016

  1. Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC)

    Carcinogenesis, Vol. 37, Núm. 8, pp. 751-758

  2. Endoscopic surveillance in patients with multiple (10-100) colorectal polyps

    Endoscopy, Vol. 48, Núm. 1, pp. 56-61

2015

  1. Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer

    Journal of Medical Genetics, Vol. 52, Núm. 7, pp. 498-502

2014

  1. Prevalence and characteristics of mutyh-associated polyposis in patients with multiple adenomatous and serrated polyps

    Clinical Cancer Research, Vol. 20, Núm. 5, pp. 1158-1168

2013

  1. Clinical subtypes and molecular characteristics of serrated polyposis syndrome

    Clinical Gastroenterology and Hepatology, Vol. 11, Núm. 6, pp. 705-711

  2. Risk of cancer in cases of suspected lynch syndrome without germline mutation

    Gastroenterology, Vol. 144, Núm. 5

2012

  1. COGENT (COlorectal cancer GENeTics) revisited

    Mutagenesis, Vol. 27, Núm. 2, pp. 143-151

  2. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer

    Gut, Vol. 61, Núm. 6, pp. 865-872

2011

  1. 5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer

    Gastroenterology, Vol. 140, Núm. 4, pp. 1174-1181

  2. Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome

    BMC Medical Genetics, Vol. 12

2010

  1. Colorectal cancer prognosis twenty years later

    World Journal of Gastroenterology, Vol. 16, Núm. 7, pp. 862-867

  2. Susceptibility genetic variants associated with colorectal cancer risk correlate with cancer phenotype

    Gastroenterology, Vol. 139, Núm. 3

2009

  1. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status

    European Journal of Cancer, Vol. 45, Núm. 3, pp. 365-373

2008

  1. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients

    Journal of Medical Genetics, Vol. 45, Núm. 9, pp. 557-563

2006

  1. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: Proposal of a new and simpler set of recommendations

    American Journal of Gastroenterology, Vol. 101, Núm. 5, pp. 1104-1111

  2. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer

    Gut, Vol. 55, Núm. 6, pp. 848-855